Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2020-01-06 17:17:20
Reporting Period:
Accepted Time:
2020-01-06 17:17:20
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1145197 Insulet Corp PODD Surgical & Medical Instruments & Apparatus (3841) 043523891
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1631895 Shacey Petrovic C/o Insulet Corporation
100 Nagog Park
Acton MA 01720
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-01-02 1,008 $169.77 95,530 No 4 F Direct
Common Stock Acquisiton 2020-01-02 12,500 $30.58 108,030 No 4 M Direct
Common Stock Disposition 2020-01-02 12,500 $169.63 95,530 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 F Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2020-01-02 12,500 $0.00 12,500 $30.58
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
67,436 2025-02-09 No 4 M Direct
  1. This transaction represents the withholding of shares upon the vesting of restricted stock units to cover the associated tax obligations.
  2. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2019.
  3. The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $167.20 to $173.00. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
  4. This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.